Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Expansion Chart Review Study - PubMed
4 hours ago
- #biologics
- #Crohn's disease
- #real-world evidence
- Comparative study on vedolizumab vs ustekinumab in biologic-naive Crohn's disease patients.
- Clinical remission and response rates were similar between vedolizumab (89.8%) and ustekinumab (89.1%).
- Mucosal healing was significantly higher with vedolizumab (91.1% vs 88.5%).
- Treatment persistence was higher with ustekinumab (80.2% vs 69.9%).
- Serious infections were more frequent with vedolizumab (2.8/100 patient-years vs 0.8/100 patient-years).
- No significant differences in serious adverse events, CD exacerbations, surgeries, or hospitalizations.